Free Drug and Access Equation: What Regeneron’s Otarmeni Decision Reveals About Specialty Product Access

Executive Summary

On April 23, 2026, Regeneron Pharmaceuticals made a decision that has no direct precedent in modern biopharmaceutical commercialization: it chose to provide Otarmeni (lunsotogene parvec-cwha), the first-ever FDA-approved gene therapy for genetic hearing loss, entirely free of charge to clinically eligible patients in the United States. Likely associated with a multimillion-dollar price tag (as most cell and gene therapies), this decision was a dramatic step towards ensuring access to a gene therapy for those who need it most.

But does “free drug” really mean “free treatment”? This brief examines both sides of that question as Regeneron’s decision brings the next layer of access barriers into focus: the tedious coordination, logistical costs, and vital role of patient support programs (PSPs) that remain in place even after the drug price is removed.

The Otarmeni Case: What Happened and Why It Matters

The Therapy

Otarmeni is an adeno-associated virus (AAV) vector-based gene therapy that delivers a functional copy of the OTOF gene directly into the cochlea, restoring the production of otoferlin protein, a critical mediator of sound signal transmission. It is indicated for pediatric and eligible adult patients with severe-to-profound sensorineural hearing loss caused by biallelic OTOF gene variants. The FDA granted accelerated approval on April 23, 2026, just 61 days after the BLA filing, making it one of the fastest biologics approvals in modern regulatory history. In the pivotal CHORD trial, 80% of participants achieved meaningful hearing restoration, and 42% achieved normal hearing, including the remarkable ability to hear whispers, with longer follow-up.

The Patient Population

OTOF-related hearing loss affects approximately 50 newborns annually in the United States. Although an ultra-rare disease, any discussions regarding access should not be limited to only newly diagnosed infants. Given Otarmeni’s indication for use in both pediatric and adult patients, those who match eligibility criteria may include both newly diagnosed children and later-identified adults. The distinction matters as experienced real-world access barriers independent of drug cost may reach past the annual incident population.

The Decision

Regeneron’s pricing decision was bundled with a broader political and commercial agreement: Most Favored Nations (MFN) pricing for Regeneron products on Medicaid, a 58% price reduction on its cholesterol drug Praluent (from $537 to $225 via TrumpRx), and a $27 billion domestic manufacturing investment commitment. In exchange, the company received three years of tariff immunity. However, while such political and commercial context holds its own relevance, it should not overshadow the pragmatic significance of Regeneron’s decision. By removing the cost of drug itself, the biotech giant has already erased one of the widely recognized barriers of gene therapy to patients and their caregivers.

Unpacking “Free”: The Financial Burdens That Remain for Treatment

Like any cell and gene therapy, the expense of receiving treatment in a safe, timely manner extends well beyond drug cost. Mandatory, costly steps associated with the decision to pursue therapy can include:

• Pre-treatment genetic testing and diagnostic workup
• Specialist referral and evaluation
• Surgical administration fees (intracochlear infusion under general anesthesia in the case of Otarmeni)
• Post-administration monitoring and follow-up
• Insurance co-pays and deductibles for facility and physician charges

For many patients and caregivers, the sum of such financial demands may be substantial. Regeneron has acknowledged that “out-of-pocket costs for administration may vary by site and payer.” Thus, the distinction between “free drug” and “free treatment” matters significantly as each patient’s access profile can widely vary. The operational and financial model required to deliver gene therapy (and all specialty products, for that matter) to patients remains a costly framework.

The Full Equation: Payers and The Role of Patient Support Programs

Payers Are Still Important

Regeneron’s decision was shaped by a unique convergence of commercial, regulatory, and patient population factors. Regardless, the access lesson it surfaces applies broadly: even when the cost of drug is removed, payers remain a critical variable in whether patients can actually receive treatment. For example, a denial of coverage for surgical administration fees alone can cause a family to abandon a therapy they believe is finally within reach, replacing one barrier with another.

The Critical Role of Patient Support Programs

The Otarmeni case emphasizes why patient support programs (PSPs) remain essential even after the cost of drug is removed. Spanning from day zero of learning of one’s diagnosis to months later during post-infusion follow-up, PSPs hold an imperative role in helping both patients and their providers successfully navigate the following:

• Receiving the appropriate genetic testing necessary to determine the right diagnosis
• Locating a specialist who is familiar with their ultra-rare condition
• Understanding treatment journey milestones and expectations for families and caregivers
• Preparing for payer coverage requirements and anticipated out-of-pocket costs
• Travel support resources in accordance with Office of Inspector General (OIG) guidelines

In such a complex landscape, the many demands required to safely surpass each cell and gene therapy care milestone is not always clearly understood, let alone affordable. In this way, Regeneron’s decision should not reduce the perceived need for patient support but should elevate it.

A best-in-class PSP model should help patients and their families not just understand what costs may remain but set them in the right direction to ensure such demands do not become a barrier. Regeneron has done just that through the availability of their own robust PSP; providing services specifically in understanding non-drug related out-of-pocket expenses and product education catered to patients and caregivers. This investment despite the fact that Ortameni is free. Such services go as far as to assist families in finding a qualified specialist who does not just complete the genetic testing for an accurate diagnosis but can further support patients in the surgical scheduling and coordination of authorized treatment centers. To their credit, this intentional infrastructure of support demonstrates Regeneron’s understanding that free drug alone will not bring patients and their families across the finish line.

Strategic Implications for Life Sciences Executives

The takeaway is not that every gene therapy should be free, but that the industry needs more novel, patient-centered access models. Such considerations may fall within the following

1. Cell and Gene Therapy Expenses Extend Beyond Drug Costs

Costs and logistics associated with the drug can be substantial and can end up being the direct culprit in patients not accessing therapy. As discussed, the added requirements of specialist evaluations, surgical fees, and various follow-up appointments each come with their own cost to patients, which are effectively untouched after the patient’s drug cost are removed. It is here where manufacturers have the impactful opportunity to provide extensive educational and access resources to assist eligible patients in finding support options that can help fill this gap.

2. Manufacturers Still Have a Role Beyond Free Drug

As the healthcare landscape continues to introduce highly specialized, one-time therapies, manufacturers and their partners will need to develop access strategies that take into consideration the full treatment journey from beginning to end, regardless of drug price. These advancements may include holistic patient and caregiver-friendly educational materials, timely payer engagement, treatment-center readiness initiatives, and other increased efforts put towards PSP evolution and customization. At its core, companies must not only evaluate how the drug will be paid for, but how patients and their providers will actually move from one step to the next throughout the treatment journey. Effectively, many steps must go correctly to access product, not just the one related to drug affordability.

Sources & References
1 Regeneron Pharmaceuticals Press Release, April 23, 2026
2 White House Fact Sheet, April 23, 2026
3 AJMC, CNBC, PBS NewsHour, Fierce Pharma, Pharmaceutical Executive, April 2026
4 PMC / NIH: “Managing the challenges of paying for gene therapy”
5 Mordor Intelligence Gene Therapy Market Report, January 2026
6 Drug Discovery Trends: 50 CGT Leaders to Watch, January 2026